CVS Health (NYSE: CVS) Stock Analysis: Financial Performance, Analyst Ratings, and Upside Potential

Font: Financial Modeling Prep  • Sep 03, 2026

• Diversified Healthcare Giant: CVS Health (NYSE:CVS) operates a vertically integrated business model, encompassing retail pharmacies, medical clinics, and its Aetna health insurance segment, solidifying its position in the broader healthcare industry.
• Robust Financial Growth: The company demonstrated strong financial performance with a 7.3% year-over-year revenue increase in Q2, reaching $106.1 billion, and subsequently raised its full-year revenue forecast to at least $414 billion, alongside improved EPS guidance.
• Analyst Confidence & Upside Potential: Despite a lowered price target from UBS, analysts maintain a positive outlook, with Jefferies confirming a buy rating and a $120.00 price target, suggesting significant upside potential for CVS stock.

CVS Health (NYSE:CVS) is a major American healthcare company. It operates a vertically integrated business model, which includes around 9,000 retail pharmacies and over 1,000 medical clinics. Through its Aetna segment, CVS is also the second-largest health insurer, giving it a wide reach across the healthcare industry.

On September 3, 2026, a UBS analyst lowered their price target for CVS Health to $118.00 from a previous target of $126.00. With the stock price at $97.23 at the time, this new target still represents a potential upside of 21.36%. An upside is the potential increase in a stock's value, indicating positive investment potential.

This potential is supported by strong financial results. The company reported second-quarter revenue of $106.1 billion, a 7.3% increase year over year. Following this, CVS Health raised its yearly revenue forecast to at least $414 billion and its earnings per share (EPS) guidance to a range between $6.84 and $7.04, showcasing robust financial performance.

CVS Health is also improving its balance sheet by focusing on deleveraging, which is the process of paying down debt. As highlighted by Zacks Investment Research, the company generated $10.6 billion in operating cash flow year to date. It also reported a leverage ratio, a key measure of debt, of about 3.5 times, demonstrating a commitment to debt reduction.

Other analysts also see potential in the company. As highlighted by The Motley Fool, a Jefferies analyst confirmed a buy rating on CVS Health with a $120.00 price target. This target suggests a 28% upside from the stock's price at the time, showing continued analyst confidence from some parts of Wall Street regarding CVS stock.